Bausch Health to pay SEC $45M to resolve dispute

Bausch Health agreed to pay the U.S. Securities and Exchange Commission $45 million to settle allegations it misled investors in reported financial figures during the 2014 and 2015 reporting periods.

What you should know:

1. Bausch Health, which was known as Valeant Pharmaceuticals during the aforementioned time period, allegedly defrauded investors in financial statements by covering up ties with mail-order pharmacy company Philidor Rx, MarketWatch reports.

2. Bausch settled all charges without admitting guilt or denying the SEC's charges.

3. The SEC recognized Bausch's efforts to conduct an investigation into the matter and provide information voluntarily to SEC staff.

4. Since the incident, Bausch rebranded the company and installed a new board and executive management team.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast